Event Archives


Biocentury’s 23rd Annual NewsMakers in the Biotech Industry

Madrigal Chairman and CEO, Dr. Paul A. Friedman, will be presenting at the 23rd annual NewsMakers in the Biotech Industry investment conference.
September 9, 2016 | New York, NY


Conference Call and Webcast

April 14, 2016 | Lexington, MA and Fort Washington, PA

Synta and Madrigal will host a conference call and webcast slide presentation at 8:30 AM ET today to discuss the Merger. The conference call and presentation can be accessed by logging on to the “Investors” section of the Synta Pharmaceuticals website, www.syntapharma.com, prior to the event.

Synta-Madrigal Corporate Slide Deck


GTC 7th Diabetes Drug Discovery and Development Conference

Complications of Type 2 Diabetes: Diabetic Dyslipidemia and NASH and potential of MGL-3196, a Phase 2 ready liver targeted thyroid receptor beta agonist
April 23-25, 2014 | Cambridge, MA


Phacilitate Metabolic Leaders’ Forum 2013

Novel Metabolic Disease Targets – How to Replenish the Reservoir?
October 16-18, 2013 | Boston, MA


SMi Diabetes 2013

MGL-3916 Liver-Directed Thyroid Hormone Beta Agonist, a Novel Treatment for Diabetic Dyslipidemia
October 1-2, 2013 | London, UK


CHI 11th Annual Discovery on Target – Cardio-Metabolic Drug Targets

Novel Treatment for Dyslipidemia: Liver-Directed Thyroid Hormone Receptor-β Agonist
September 25-26, 2013 | Boston, MA


GTC Diabetes Summit 2013

Novel Treatment for Diabetic Dyslipidemia: Rapid and Robust Lowering of LDL, Non-HDL Cholesterol, Apolipoprotein B and Triglycerides after Multiple Doses of MGL-3196, Liver-Directed Thyroid Hormone Receptor-ß Agonist in Phase 1 Studies
April 29-30, 2013 | Boston, MA


Madrigal Pharmaceuticals Discloses the Structure and Enhanced Safety Properties of MGL-3196 at the 245th American Chemical Society National Meeting and Exposition

April 10, 2013


245th ACS National Meeting and Exposition

280 – Discovery and development of MGL-3196, a liver-directed thyroid hormone beta agonist for the treatment of hypercholesterolemia/dyslipidemia and hypertriglyceridemia
April 10, 2013, 4:20pm | First Time Disclosures Session, Morial Convention Center, Room R02-R04 | New Orleans, Louisiana


Diabetes, Cardiovascular & Renal Complications

Nov 28-29, 2012 | London, UK


American Heart Association Scientific Sessions 2012

11958 – Pharmacokinetics, Safety and Cholesterol Lowering in Healthy Volunteers Treated with Single and Multiple Doses of Madrigal’s 3196 Liver-directed Thyroid Hormone Receptor-ß Agonist
Nov 06, 2012, 9:30 AM -11:00 AM | Kentia Hall, Core 2, Poster Board: 2005 | Los Angeles, CA


Madrigal Pharmaceuticals Announces Results From MGL-3196 Multiple Dose Study at the American Heart Association 2012 Scientific Sessions

Nov 6, 2012


Dyslipidemia Targets and Diabetes

Diabetes Drug Discovery and Beyond 
October 2-3, 2012 | Boston, MA


10th International Workshop on Resistance to Thyroid Hormone and Thyroid Hormone Action

September 17-19 | Quebec, Canada


Opportunities in Novel Targets to Treat Metabolic and Cardiovascular Diseases

Early Stage Clinical Development
May 29-31, 2012 | Boston, MA


Targeting Diabetic Dyslipidaemia Using Novel Drugs

Visiongain’s 6th Annual Diabetes Conference
April 25-26, 2012 | Thistle City Barbican, London, UK


Innovative Treatments for Cardiometabolic Diseases

GTC Bio 2nd Diabetes Summit
April 19-20, 2012 | Boston, MA


Opportunities in Dyslipidemia Treatment, LDL Versus HDL

Phacilitate Metabolic Leaders’ Forum West 2012
March 12-14, 2012 | San Francisco, CA


Madrigal Pharmaceuticals Launches Multiple Dose Phase I Clinical Study for 3196 in Dyslipidemia

March 5, 2012


Innovative Treatments for Cardiometabolic Diseases

Biotech Showcase 2012
January 10, 2012 | San Francisco, CA


Targeting the Lipid Component of Diabetes

CHI Discovery on Target; Diabetes Track
November 3, 2011 | Boston, MA


Discovery and Preclinical Development of an Innovative Metabolic Disease Treatment

CBI Pharma/Bio Forum on Preclinical Development
September 27, 2011 | Boston, MA